Trial Profile
Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Betrixaban (Primary)
- Indications Stroke; Thromboembolism
- Focus Pharmacokinetics
- Sponsors Portola Pharmaceuticals
- 23 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
- 02 Nov 2009 New trial record